6533b823fe1ef96bd127e2f0

RESEARCH PRODUCT

Ambulatory treatment of low-risk pulmonary embolism in fragile patients: a subgroup analysis of the multinational Home Treatment of Pulmonary Embolism (HoT-PE) Trial

subject

description

Pulmonary embolism is the third most frequent acute cardiovascular disease with an annual incidence of approximately 100 cases per 100 000 population and an annual mortality of ≥7 deaths per 100 000 population in the European region [1, 2]. Initial management is adjusted to the risk of in-hospital death or early complications, which depend both on the severity of pulmonary embolism and the presence of comorbidities [3]. Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Conflict of interest: Dr. Hobohm reports grants from German Federal Ministry of Education and Research (BMBF 01EO1503), during the conduct of the study; personal fees from MSD, personal fees from Actelion, outside the submitted work. Conflict of interest: Dr. Anusic reports grants from German Federal Ministry of Education and Research (BMBF 01EO1503), during the conduct of the study Conflict of interest: Dr. Konstantinides reports grants from German Federal Ministry of Education and Research (BMBF 01EO1503), during the conduct of the study; grants and personal fees from Boehringer Ingelheim, grants and personal fees from Bayer, grants and personal fees from Daiichi-Sankyo, personal fees from MSD, grants and personal fees from Pfizer – Bristol-Myers Squibb, grants from Actelion, outside the submitted work. Conflict of interest: Dr. Barco reports grants from German Federal Ministry of Education and Research (BMBF 01EO1503), during the conduct of the study; personal fees from Bayer Health Care, personal fees from BTG Pharmaceuticals, personal fees from Leo Pharma, personal fees from Daiichi Sankyo, outside the submitted work.